The global ulcerative colitis drug market is expected to grow from USD 6.81 billion in 2019 to USD 10.10 billion by 2027, at a CAGR of 4.34% during the forecast period  to 2027.

Ulcerative colitis drug market is experiencing a substantial growth, owing to increasing prevalence rate of ulcerative colitis across the globe. Many medication are available for the treatment of ulcerative colitis in the market, but depends upon the cause and nature of the disease. Nowadays, many companies are heavily investing in the research and development activities to launch the innovative drugs for the ulcerative colitis, and some companies have many product in their pipeline waiting for the approval, driving the growth of market.

Ulcerative colitis is an inflammatory bowel disease (IBD) of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers that causes ulcers (sores) and long-lasting inflammation in the digestive tract. At present, there is no cure for ulcerative colitis, but some medication are available for the treatment of this disease. Several categories of drugs are available in the market in treating ulcerative colitis. The main focus of these drugs to minimize & control the signs and symptoms of the disease. The treatment and drugs are depend on the severity of condition of patient and location of ulcerative colitis.

Global ulcerative colitis drug market is expected to witness rapid growth over the forecast period, owing to growing prevalence and incidences of ulcerative colitis across the globe. The adverse side effects of ulcerative colitis drug on health and lack of public awareness about ulcerative colitis disease and its treatment, may hinder the market growth over the forecast period. However, ongoing research and development to launch the new drugs and opportunity to develop the generic drugs, are some of the factors, offering the future growth opportunities for the vendors in the market. 

Key players operating in the global ulcerative colitis drug market are Bausch Health Companies Inc. (Salix Pharmaceutical), AbbVie Inc., Johnson and Johnson, Boehringer Ingelheim GmbH, Novartis AG, Merck & Co., Teva Pharmaceuticals Ltd., Takeda Pharmaceuticals, Shire, Pfizer Inc. among others. To enhance their market position in the global ulcerative colitis drug Industry, the key players are now focusing on adopting the strategies such as recent developments, product innovation, mergers & acquisitions, joint venture, collaborations, and partnership.

• For instance, in December 2017, Boehringer Ingelheim announced the partnership with the Roche, for the development of orally available novel Locked Nucleic Acid (LNA) oligonucleotides for the treatment of inflammatory bowel diseases (IBDs).
• In June 2018, Merck & Co. announced the launch of RENFLEXIS (infliximab-abda), a Biosimilar of the originator biologic medicine Remicade (infliximab) in the U.S. for the treatment of ulcerative colitis.

Biologics accounted for the major market share and valued at USD 2.99 billion in 2019

The type segment is divided into biologics, corticosteroids, immunomodulators, 5-aminosalicylic acid, immunosuppressant, biosimilars, and others. Biologics accounted for the major market share and valued at USD 2.99 billion in 2019. Biologics drugs works on selective manner, rather than effecting on the whole body, thus, people prefers biologics more than any other drugs, fuelling the growth of market.

Oral segment is anticipated to grow at the highest CAGR of 5.4% over the forecast period

The route of administration segment is classified into oral and injectable. Oral segment is anticipated to grow at the highest CAGR of 5.4% over the forecast period. This is mainly sue to presence of strong pipeline products and ongoing research and development activities to develop new oral dugs for the treatment of ulcerative colitis.

The hospital pharmacy segment held the largest market share of 46.2% in the year 2019.

The distribution channel segment includes hospital pharmacy, retail pharmacy, and online pharmacy.  The hospital pharmacy segment held the largest market share of 46.2% in the year 2019. Increasing ulcerative colitis patient worldwide, led to an increase in the total number of hospitalizations worldwide, results into growth of hospital pharmacy segment.

Ulcerative proctitis segment accounted for the largest market share and valued at USD 3.89 billion in 2019

The application segment is divided into proctosigmoiditis, ulcerative proctitis, pancolitis, left-sided colitis, acute severe ulcerative colitis, and others. Ulcerative proctitis segment accounted for the largest market share and valued at USD 3.89 billion in 2019. It is considered as the first manifestation of ulcerative colitis. Thus, growing prevalence of ulcerative proctitis, boosting the growth market.

Regional Segment Analysis of the Ulcerative Colitis Drug Market

• North America (U.S. , Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of the Europe)
• Asia-Pacific (China, Japan India, Rest of APAC)
• South America (Brazil and Rest of South America)
• Middle East and Africa (UAE, South Africa, Rest of MEA)

The regions analysed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. The North America region emerged as the largest market for the ulcerative colitis drug market with a 44.3% share of the market revenue in 2019. This is because North America is growing tremendously in terms of the healthcare industry. North America region has become the hub for the technological development and transformation of the industry. Asia Pacific region is anticipated to grow at highest CAGR of 7.9% over the forecast period in the global ulcerative colitis drug market. Growing health awareness among the consumers and rising healthcare expenditure in the region, driving the growth of market. 

The global ulcerative colitis drug industry is analysed on the basis of value (USD Billion). All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, and competitor position grid analysis.